Ian Ying Woo - 18 Mar 2026 Form 3 Insider Report for NovaBridge Biosciences (NBP)

Role
Director
Signature
/s/ Xi-Yong (Sean) Fu as attorney-in-fact
Issuer symbol
NBP
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 21:30:28 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Woo Ian Ying Director C/O NOVABRIDGE BIOSCIENCES,, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE /s/ Xi-Yong (Sean) Fu as attorney-in-fact 18 Mar 2026 0002115245

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NBP 2025 Employee Share Option (right to buy) 18 Mar 2026 Ordinary Shares 15,850 $6.13 Direct F1, F2, F3
holding NBP Restricted Share Units 18 Mar 2026 Ordinary Shares 17,310 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2 Number of underlying securities and exercise price expressed in terms of ADSs
F3 The option was granted on October 15, 2025. The option vests and becomes exercisable in three equal annual installments beginning on the first anniversary of the grant date.
F4 On October 15, 2025, the Reporting Person was granted 17,310 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vest over three years in equal annual installments on October 15, 2026, 2027 and 2028.

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney